Drug intelligence / Profile preview

6'-sialyllactose

Development stage
Preclinical
Lead developer
DSM-Firmenich
Modality
Microbiome Therapeutics
Administration
Oral
01

Overview

6'-Sialyllactose (6'-SL) is a sialylated human milk oligosaccharide (HMO) that is naturally occurring in human breast milk. Developed by Glycosyn as a nutritional ingredient and prebiotic, it is primarily intended for use in infant formula and dietary supplements to support digestive health, immune function, and general wellness. As a prebiotic oligosaccharide, 6'-SL selectively promotes the growth of beneficial gut bacteria, such as *Bifidobacterium* and *Lactobacillus*, while inhibiting the adhesion of harmful pathogens to the intestinal mucosa. Furthermore, 6'-SL serves as a source of sialic acid, which is a critical component for brain development, specifically in the formation of gangliosides and the myelination of nerve cells. Glycosyn is also conducting preclinical research to explore the potential of 6'-SL in treating or preventing medical conditions such as necrotizing enterocolitis (NEC), inflammatory bowel disease (IBD), and infectious diarrhea.

Other names
6-sialyllactose6'-Sialyllactose sodium saltN-acetylneuraminyl-alpha2-6-lactoseN-acetylneuraminyl-alpha-2-6-lactoseN-acetylneuraminyl-alpha 2-6-lactose

Beyond the preview

Go deeper on 6'-sialyllactose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6'-sialyllactose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call